COHEN & STEERS INC (CNS) Stock Fundamental Analysis
NYSE:CNS - New York Stock Exchange, Inc. - US19247A1007 - Common Stock - Currency: USD
Overall CNS gets a fundamental rating of 5 out of 10. We evaluated CNS against 225 industry peers in the Capital Markets industry. CNS has only an average score on both its financial health and profitability. CNS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CNS was profitable.
CNS had a positive operating cash flow in the past year.
Each year in the past 5 years CNS has been profitable.
Of the past 5 years CNS 4 years had a positive operating cash flow.
1.2 Ratios
CNS has a better Return On Assets (18.59%) than 98.17% of its industry peers.
CNS has a better Return On Equity (27.55%) than 95.43% of its industry peers.
CNS has a better Return On Invested Capital (23.49%) than 99.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.59% | ||
| ROE | 27.55% | ||
| ROIC | 23.49% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 27.23%, CNS is doing good in the industry, outperforming 67.12% of the companies in the same industry.
In the last couple of years the Profit Margin of CNS has declined.
CNS has a Operating Margin of 32.49%. This is comparable to the rest of the industry: CNS outperforms 54.79% of its industry peers.
In the last couple of years the Operating Margin of CNS has declined.
CNS has a better Gross Margin (89.06%) than 90.87% of its industry peers.
CNS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.49% | ||
| PM (TTM) | 27.23% | ||
| GM | 89.06% |
OM growth 3Y-7.34%
OM growth 5Y-1.86%
PM growth 3Y-7.86%
PM growth 5Y-2.87%
GM growth 3Y0.87%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CNS has an Altman-Z score of 12.17. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
CNS's Altman-Z score of 12.17 is amongst the best of the industry. CNS outperforms 95.43% of its industry peers.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.17 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNS has a Current Ratio of 0.92. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS has a Current ratio (0.92) which is in line with its industry peers.
CNS has a Quick Ratio of 0.92. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.92, CNS is in line with its industry, outperforming 43.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.92 | ||
| Quick Ratio | 0.92 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.53% over the past year.
CNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.50% yearly.
CNS shows a small growth in Revenue. In the last year, the Revenue has grown by 5.40%.
CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.39% yearly.
EPS 1Y (TTM)3.53%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%16.42%
Revenue 1Y (TTM)5.4%
Revenue growth 3Y-2.93%
Revenue growth 5Y5.39%
Sales Q2Q%3%
3.2 Future
CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.77% yearly.
Based on estimates for the next years, CNS will show a small growth in Revenue. The Revenue will grow by 5.51% on average per year.
EPS Next Y7.89%
EPS Next 2Y9.53%
EPS Next 3Y9.99%
EPS Next 5Y11.77%
Revenue Next Year4.43%
Revenue Next 2Y5.54%
Revenue Next 3Y7.06%
Revenue Next 5Y5.51%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 29.46, the valuation of CNS can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of CNS indicates a slightly more expensive valuation: CNS is more expensive than 72.15% of the companies listed in the same industry.
CNS is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 27.31 indicates a quite expensive valuation of CNS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CNS indicates a slightly more expensive valuation: CNS is more expensive than 70.78% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CNS to the average of the S&P500 Index (22.68), we can say CNS is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.46 | ||
| Fwd PE | 27.31 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than the industry average as 68.04% of the companies are valued more expensively.
CNS's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.82 | ||
| EV/EBITDA | 24.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
CNS has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.73
PEG (5Y)11.8
EPS Next 2Y9.53%
EPS Next 3Y9.99%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 2.87%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 9.98, CNS has a dividend in line with its industry peers.
CNS's Dividend Yield is a higher than the S&P500 average which is at 2.27.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.87% |
5.2 History
The dividend of CNS decreases each year by -9.78%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-9.78%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
CNS pays out 86.70% of its income as dividend. This is not a sustainable payout ratio.
DP86.7%
EPS Next 2Y9.53%
EPS Next 3Y9.99%
86.33
-0.21 (-0.24%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners60.13%
Inst Owner Change-85.07%
Ins Owners23.14%
Ins Owner Change-0.36%
Market Cap4.36B
Analysts76.67
Price Target95.88 (11.06%)
Short Float %5.85%
Short Ratio7.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.87% |
Yearly Dividend2.3
Dividend Growth(5Y)-9.78%
DP86.7%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.89%
Min EPS beat(2)-2.26%
Max EPS beat(2)0.49%
EPS beat(4)2
Avg EPS beat(4)-0.13%
Min EPS beat(4)-2.38%
Max EPS beat(4)3.65%
EPS beat(8)4
Avg EPS beat(8)1.04%
EPS beat(12)8
Avg EPS beat(12)2.87%
EPS beat(16)12
Avg EPS beat(16)3.94%
Revenue beat(2)1
Avg Revenue beat(2)2.71%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)6.21%
Revenue beat(4)1
Avg Revenue beat(4)-0.34%
Min Revenue beat(4)-3.96%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.74%
PT rev (3m)-11.74%
EPS NQ rev (1m)-3.73%
EPS NQ rev (3m)-3.73%
EPS NY rev (1m)-12.89%
EPS NY rev (3m)-12.89%
Revenue NQ rev (1m)-3.52%
Revenue NQ rev (3m)-3.52%
Revenue NY rev (1m)-8.49%
Revenue NY rev (3m)-11.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.46 | ||
| Fwd PE | 27.31 | ||
| P/S | 8.79 | ||
| P/FCF | 43.82 | ||
| P/OCF | 36.24 | ||
| P/B | 8.89 | ||
| P/tB | 9.26 | ||
| EV/EBITDA | 24.69 |
EPS(TTM)2.93
EY3.39%
EPS(NY)3.16
Fwd EY3.66%
FCF(TTM)1.97
FCFY2.28%
OCF(TTM)2.38
OCFY2.76%
SpS9.83
BVpS9.71
TBVpS9.33
PEG (NY)3.73
PEG (5Y)11.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.59% | ||
| ROE | 27.55% | ||
| ROCE | 30.61% | ||
| ROIC | 23.49% | ||
| ROICexc | 29.43% | ||
| ROICexgc | 33.5% | ||
| OM | 32.49% | ||
| PM (TTM) | 27.23% | ||
| GM | 89.06% | ||
| FCFM | 20.05% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-7.34%
OM growth 5Y-1.86%
PM growth 3Y-7.86%
PM growth 5Y-2.87%
GM growth 3Y0.87%
GM growth 5Y0.62%
F-Score6
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 188.31% | ||
| Cap/Sales | 4.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 69.84% | ||
| Profit Quality | 73.65% | ||
| Current Ratio | 0.92 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z | 12.17 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.53%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%16.42%
EPS Next Y7.89%
EPS Next 2Y9.53%
EPS Next 3Y9.99%
EPS Next 5Y11.77%
Revenue 1Y (TTM)5.4%
Revenue growth 3Y-2.93%
Revenue growth 5Y5.39%
Sales Q2Q%3%
Revenue Next Year4.43%
Revenue Next 2Y5.54%
Revenue Next 3Y7.06%
Revenue Next 5Y5.51%
EBIT growth 1Y-6.91%
EBIT growth 3Y-10.06%
EBIT growth 5Y3.42%
EBIT Next Year50.56%
EBIT Next 3Y24.45%
EBIT Next 5Y7.49%
FCF growth 1Y-19.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.74%
OCF growth 3YN/A
OCF growth 5YN/A